Modeling epithelial plasticity-induced erlotinib resistance in non-small cell lung cancer.

被引：0
|
作者：
Wang, Hailun [1 ]
Cades, Jessica [1 ]
Yochum, Zachary [2 ]
Nugent, Katriana [1 ]
Rudin, Charles [3 ]
Burns, Timothy [2 ]
Phuoc Tran [1 ]
机构：
[1] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[2] Univ Pittsburgh, Pittsburgh, PA USA
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 10期
关键词：
D O I：
10.1158/1538-7445.MOUSEMODELS17-B47
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B47
引用
收藏
页码：77 / 78
页数：2
相关论文
共 50 条
  • [41] Role of emt biomarkers in mediating osimertinib resistance in non-small cell lung cancer.
    Racherla, Kavya Sri
    Dovalovsky, Katrina
    Puri, Neelu
    CANCER RESEARCH, 2021, 81 (13)
  • [42] FGFR1 upregulation causes resistance to erlotinib in non-small cell lung cancer cell lines
    Jacobsen, K.
    Beck, H. C.
    Ditzel, H. J.
    EUROPEAN JOURNAL OF CANCER, 2016, 61 : S166 - S166
  • [43] An electroporation platform for Erlotinib resistance screening in living non-small cell lung cancer (NSCLC) cells
    Yan, Z.
    Hui, T. H.
    Fong, H. W.
    Shao, X.
    Cho, W. C.
    Ngan, K. C.
    Yip, T. C.
    Lin, Y.
    BIOMEDICAL PHYSICS & ENGINEERING EXPRESS, 2018, 4 (02):
  • [44] Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer
    Xie, Caifeng
    Jin, Jiangbo
    Bao, Xujie
    Zhan, Wei-Hua
    Han, Tian-Yu
    Gan, Mingxi
    Zhang, Chengfu
    Wang, Jianbin
    ONCOTARGET, 2016, 7 (01) : 610 - 621
  • [45] Aberrantly expressed microRNAs drive the development of acquired Erlotinib resistance in non-small cell lung cancer
    Pal, Arpita S.
    Agredo, Alejandra
    Kasinski, Andrea L.
    CANCER RESEARCH, 2017, 77
  • [46] Fatal interstitial lung disease after erlotinib for non-small cell lung cancer
    Lind, Joline S. W.
    Smit, Egbert F.
    Grunberg, Katrien
    Senan, Suresh
    Lagerwaard, Frank. J.
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (09) : 1050 - 1053
  • [47] A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer.
    Giaccone, G
    Lechevalier, T
    Thatcher, N
    Smit, E
    Janmaat, M
    Rodriguez, J
    Oulid-Aissa, D
    Soria, JC
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 638S - 638S
  • [48] Drug resistance in non-small cell lung cancer
    Monzo, M
    Rosell, R
    Taron, M
    LUNG CANCER, 2001, 34 : S91 - S94
  • [49] Trends in ALK inhibitors for non-small cell lung cancer.
    Meade, Denise
    Ng, Marie
    Alford, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [50] Immunological markers of outcome of non-small cell lung cancer.
    Potter, DA
    Amin, C
    Mohiuddin, A
    Badve, S
    Davidson, D
    Kesler, K
    Hanna, N
    Edenberg, H
    Einhorn, L
    Mitra, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 678S - 678S
12345